EXASCAUTIOUS

EXAS Revenue Growth (YoY) Analysis

23.1%

Higher than 84% of Healthcare sector peers

Updated 2555h ago·SEC filings & market data

Key Takeaway

EXAS (EXAS) has a Revenue Growth (YoY) of 23.1% as of May 2026.

Sector Performance

84th percentile

EXAS

23.1%

Sector Median

8.9%

Sector Avg

12.2%

📊

Deep Analysis

EXAS (EXAS) has a Revenue Growth (YoY) of 23.1% as of May 2026.

This places EXAS in the 84th percentile of the Healthcare sector, which has a median Revenue Growth (YoY) of 8.9% and a sector average of 12.2%. EXAS's Revenue Growth (YoY) is 159.6% above the sector median, a significant divergence that warrants closer examination. In context: Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about EXAS?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does EXAS's Revenue Growth (YoY) compare to its sector?

EXAS's Revenue Growth (YoY) of 23.1% compares to a Healthcare sector median of 8.9%, placing it in the 84th percentile.

Who are EXAS's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: A (10.0%), ABT (7.8%), DGX (10.2%), RVTY (7.0%), CAH (11.0%).

📚

Learn More About Revenue Growth (YoY)

How to Analyze Revenue Growth: More Than Just Rising Sales

Learn how to analyze revenue growth beyond the headline number. Master absolute vs percentage, YoY vs QoQ, and sustainable growth with real examples from NVDA, GOOGL, and MDB.

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.